Please sign in to follow a disease.
Vaginal neoplasm
MONDO:0021050A benign or malignant neoplasm affecting the vagina. Representative examples of benign neoplasms include squamous papilloma and melanocytic nevus. Representative examples of malignant neoplasms include carcinoma, melanoma, and sarcoma.
Also known as: neoplasm of the vagina, neoplasm of vagina, tumor of the vagina, tumor of vagina, tumour of the vagina, tumour of vagina, vagina neoplasm, vagina neoplasm (disease)
1490 clinical trials for this condition and its sub-types, 2 tagged with Vaginal neoplasm itself.
Follow this condition to get notified about new trialsWhere it sits in the disease tree
Browse by category →Sub-types of Vaginal neoplasm
-
Vaginal cancer 53 trials · 60 incl. sub-types
5 sub-types
- Vaginal carcinoma 12 trials · 22 incl. sub-types Sub-types →
- Malignant vaginal mixed epithelial and mesenchymal neoplasm 0 trials Sub-types →
- Vagina sarcoma 0 trials Sub-types →
- Vaginal adenosarcoma 0 trials
- Vaginal germ cell malignant tumor 0 trials Sub-types →
-
Vaginal squamous tumor 0 trials · 8 incl. sub-types
2 sub-types
- Vaginal squamous cell carcinoma 8 trials
- Vaginal squamous papilloma 0 trials
-
Vaginal glandular neoplasm 0 trials · 7 incl. sub-types
3 sub-types
- Vaginal adenocarcinoma 7 trials Sub-types →
- Vaginal adenoma 0 trials Sub-types →
- Vaginal mullerian papilloma 0 trials
-
Vaginal melanoma 1 trial
-
Benign vaginal neoplasm 0 trials
4 sub-types
- Benign vaginal mixed epithelial and mesenchymal neoplasm 0 trials Sub-types →
- Vaginal leiomyoma 0 trials
- Vaginal mullerian papilloma 0 trials
- Vaginal squamous papilloma 0 trials
-
1 sub-type
Most studied deeper sub-types
-
New hope for rare ovarian cancer: immunotherapy combo tested in phase II trial
Disease control Recruiting nowThis phase II trial is testing whether the immunotherapy drug dostarlimab, alone or combined with bevacizumab, can control recurrent gynecological clear cell carcinoma better than standard chemotherapy. About 198 women with this rare cancer type will be randomly assigned to one o…
Phase 2 • Sponsor: Yonsei University • Aim: Disease control
Last updated Jun 27, 2026 12:29 UTC
-
New hope for rare cancers: immunotherapy drug targets tumors regardless of origin
Disease control Recruiting nowThis study tests the drug nivolumab in people with advanced rare cancers that have a specific marker (PD-L1). The goal is to see if the drug can shrink or control the tumors when other treatments have stopped working. Up to 28 adults will receive treatment for up to 12 months, an…
Phase 2 • Sponsor: Instituto do Cancer do Estado de São Paulo • Aim: Disease control
Last updated Jun 27, 2026 12:08 UTC